Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Acura Pharmaceuticals has filed a Form 12b-25 indicating a delay in submitting its Form 10-Q (Quarter Report) for the period ending September 30, 2025. The primary reason for the delay is the company’s liquidity issues, which have affected its ability to meet daily operational obligations. Acura Pharmaceuticals is currently reliant on loans from Abuse Deterrent Pharma, LLC to sustain its operations, but there is no assurance that these loans will continue or be sufficient for long-term needs. The company has not filed its annual reports for 2022, 2023, and 2024, nor its quarterly reports for any periods in 2022, 2023, 2024, and the first three quarters of 2025. Acura Pharmaceuticals anticipates filing the delayed report within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the corresponding period of the last fiscal year. The company continues to seek funding solutions to address its financial challenges. The notification was signed by Robert A. Seiser, SVP & CFO, on November 21, 2025.
More about Acura Pharmaceuticals
Technical Sentiment Signal: Sell
Current Market Cap: $13.2K
For an in-depth examination of ACUR stock, go to TipRanks’ Overview page.